Genetic screening to improve the diagnosis of familial hypercholesterolemia

References

• Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: The Metabolic and Molecular Basis of Inherited Disease. Scriver CR, Beaudet AL, Sly WS et al. (Eds). McGraw-Hill, NY, USA, 2863–2913 (2001).
   Google Scholar
• Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J. Clin. Invest. 111(12), 1795–1804 (2003).
   Google Scholar
• Naoumova RP, Thompson GR, Soutar AK. Current management of severe homozygous hypercholesterolaemias. Curr. Opin. Lipidol. 15(4), 413–422 (2004).
   Google Scholar
• Macchiaiolo M, Gagliardi MG, Toscano A, Guccione P, Bartuli A. Homozygous familial hypercholesterolaemia. Lancet 379(9823), e1330 (2012).
   Google Scholar
• Van Der Graaf A, Avis HJ, Kusters DM et al. Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children. Circulation 123(11), 1167–1173 (2011).
   Google Scholar
• Williams RR, Hunt SC, Schumacher MC et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 72(2), 171–176 (1993).
   Google Scholar
• WHO. Familial hypercholesterolemia – report of a second WHO Consultation. (WHO publication no. WHO/HGN/ HF/CONS/99.2) (1999).
   Google Scholar
• Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168(1), 1–14 (2003).
   Google Scholar
• Goldberg AC, Hopkins PN, Toth PP et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5(3), 133–140 (2011).
   Google Scholar
• Humphries S, Whittall R, Hubbart C et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J. Med. Genet. 43(12), 943–949 (2006).
   Google Scholar
• Usifo E, Leigh SE, Whittall RA et al. Low‐density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann. Hum. Genet. 76(5), 387–401 (2012). • A Comprehensive Database Of LDLR And PCSK9 Gene Variants.
   Google Scholar
• Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu. Rev. Genet. 24, 133–170 (1990).
   Google Scholar
• Bourbon M, Duarte MA, Alves AC, Medeiros AM, Marques L, Soutar AK. Genetic diagnosis of familial hypercholesterolaemia: the importance of functional analysis of potential splice-site mutations. J. Med. Genet. 46(5), 352–357 (2009).
   Google Scholar
• Kulseth MA, Berge KE, Bogsrud MP, Leren TP. Analysis of LDLR mRNA in patients with familial hypercholesterolemia revealed a novel mutation in intron 14, which activates a cryptic splice site. J. Hum. Genet. 55(10), 676–680 (2010).
   Google Scholar
• Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu. Rev. Genet. 24(1), 133–170 (1990).
   Google Scholar
• Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum. Mutat. 1(6), 445–466 (1992).
   Google Scholar
• Vohl MC, Gaudet D, Moorjani S et al. Comparison of the effect of two low‐density lipoprotein receptor class mutations on coronary heart disease among French‐Canadian patients heterozygous for familial hypercholesterolaemia. Eur. J. Clin. Invest. 27(5), 366–373 (1997).
   Google Scholar
• Lima Santos Junior PC, Morgan AC, Lepski CE et al. Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia. Atherosclerosis 233(1), 206–210 (2014).
   Google Scholar
• LDLR mutation database. www.ucl.ac.uk/ldlr/
   Google Scholar
• Segrest JP, Jones MK, De Loof H, Dashti N. Structure of apolipoprotein B-100 in low density lipoproteins. J. Lipid Res. 42(9), 1346–1367 (2001).
   Google Scholar
• Innerarity TL, Mahley RW, Weisgraber KH et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J. Lipid Res. 31(8), 1337–1349 (1990).
   Google Scholar
• Fouchier SW, Defesche JC, Kastelein JJ, Sijbrands EJ. Familial defective apolipoprotein B versus familial hypercholesterolemia: an assessment of risk. Semin. Vasc. Med. 4(3), 259–264 (2004).
   Google Scholar
• Borén J, Ekström U, Ågren, B, Nilsson-Ehle P, Innerarity TL. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J. Biol. Chem. 276(12), 9214–9218 (2001).
   Google Scholar
• Alves AC, Etxebarria A, Soutar AK, Martin C, Bourbon M. Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia. Hum. Mol. Genet. 23(7), 1817–1828 (2013).
   Google Scholar
• Thomas ER, Atanur SS, Norsworthy PJ et al. Identification and biochemical analysis of a novel APOB mutation that causes autosomal dominant hypercholesterolemia. Mol. Genet. Genomic Med. 1(3), 155–161 (2013).
   Google Scholar
• Seidah NG, Benjannet S, Wickham L et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl Acad. Sci. USA 100(3), 928–933 (2003).
   Google Scholar
• Kwon HJ, Lagace TA, Mcnutt MC, Horton JD, Deisenhofer J. Molecular basis for LDL receptor recognition by PCSK9. Proc. Natl Acad. Sci. USA 105(6), 1820–1825 (2008).
   Google Scholar
• Zhang DW, Lagace TA, Garuti R et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282(25), 18602–18612 (2007).
   Google Scholar
• Piper DE, Jackson S, Liu Q et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 15(5), 545–552 (2007).
   Google Scholar
• Cunningham D, Danley DE, Geoghegan KF et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14(5), 413–419 (2007).
   Google Scholar
• Chiou K-R, Charng M-J. Detection of mutations and large rearrangements of the low-density lipoprotein receptor gene in Taiwanese patients with familial hypercholesterolemia. Am. J. Cardiol. 105(12), 1752–1758 (2010).
   Google Scholar
• Hooper AJ, Nguyen LT, Burnett JR et al. Genetic analysis of familial hypercholesterolaemia in Western Australia. Atherosclerosis 224(2), 430–434 (2012).
   Google Scholar
• Wang J, Ban MR, Hegele RA. Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia. J. Lipid Res. 46(2), 366–372 (2005).
   Google Scholar
• Chiou KR, Charng MJ, Chang HM. Arraybased resequencing for mutations causing familial hypercholesterolemia. Atherosclerosis 216(2), 383–389 (2011).
   Google Scholar
• Holla ØL, Teie C, Berge KE, Leren TP. Identification of deletions and duplications in the low density lipoprotein receptor gene by MLPA. Clin. Chim. Acta 356(1), 164–171 (2005).
   Google Scholar
• Romano M, Di Taranto MD, D’agostino MN et al. Identification and functional characterization of LDLR mutations in familial hypercholesterolemia patients from Southern Italy. Atherosclerosis 210(2), 493–496 (2010).
   Google Scholar
• Alonso R, Defesche JC, Tejedor D et al. Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform. Clin. Biochem. 42(9), 899–903 (2009).
   Google Scholar
• Palacios L, Grandoso L, Cuevas N et al. Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis 221(1), 137–142 (2012).
   Google Scholar
• Stef MA, Palacios L, Olano-Martín E et al. A DNA microarray for the detection of point mutations and copy number variation causing familial hypercholesterolemia in Europe. J. Mol. Diagn. 15(3), 362–372 (2013). •• Evaluation Of A Unique Platform, Lipochip®, Developed To Identify Common Familial Hypercholesterolemia-Causing Mutations In European Populations.
   Google Scholar
• Tejedor D, Castillo S, Mozas P et al. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin. Chem. 51(7), 1137–1144 (2005).
   Google Scholar
• Dušková L, Kopečková L, Jansová E et al. An APEX-based genotyping microarray for the screening of 168 mutations associated with familial hypercholesterolemia. Atherosclerosis 216(1), 139–145 (2011).
   Google Scholar
• Wright WT, Heggarty SV, Young IS et al. Multiplex MassARRAY spectrometry (iPLEX) produces a fast and economical test for 56 familial hypercholesterolaemiacausing mutations. Clin. Genet. 74(5), 463–468 (2008).
   Google Scholar
• Faiz F, Allcock RJ, Hooper AJ, Van Bockxmeer FM. Detection of variations and identifying genomic breakpoints for large deletions in the LDLR by Ion Torrent semiconductor sequencing. Atherosclerosis 230(2), 249–255 (2013).
   Google Scholar
• Futema M, Plagnol V, Whittall RA, Neil HaW, Humphries SE. Use of targeted exome sequencing as a diagnostic tool for familial hypercholesterolaemia. J. Med. Genet. 49(10), 644–649 (2012).
   Google Scholar
• Hollants S, Redeker EJ, Matthijs G. Microfluidic amplification as a tool for massive parallel sequencing of the familial hypercholesterolemia genes. Clin. Chem. 58(4), 717–724 (2012).
   Google Scholar
• Metzker ML. Sequencing technologies — the next generation. Nat. Rev. Genet. 11(1), 31–46 (2009).
   Google Scholar
• Vandrovcova J, Thomas ERA, Atanur SS et al. The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia. Genet. Med. 15(12), 948–957 (2013). •• Demonstrates The Successful Use Of Two Different Massively Parallel Sequencing Platforms To Identify Mutations In A Familial Hypercholesterolemia Cohort.
   Google Scholar
• Hinchcliffe M, Le H, Fimmel A et al. Diagnostic validation of a familial hypercholesterolaemia cohort provides a model for using targeted next generation DNA sequencing in the clinical setting. Pathology 46(1), 60–68 (2014).
   Google Scholar
• Maglio C, Mancina RM, Motta BM et al. Genetic diagnosis of familial hypercholesterolaemia by targeted next‐generation sequencing. J. Intern. Med. 276(4), 396–403 (2014).
   Google Scholar
• Bodi K, Perera A, Adams P et al. Comparison of commercially available target enrichment methods for next-generation sequencing. J. Biomol. Tech. 24(2), 73–86 (2013).
   Google Scholar
• Loman NJ, Misra RV, Dallman TJ et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat. Biotechnol. 30(5), 434–439 (2012).
   Google Scholar
• Bourbon M, Sun X, Soutar A. A rare polymorphism in the low density lipoprotein (LDL) gene that affects mRNA splicing. Atherosclerosis 195(1), e17–e20 (2007).
   Google Scholar
• Liguori R, Argiriou A, Simone VD. A rapid method for detecting mutations of the human LDL receptor gene by complete cDNA sequencing. Mol. Cell. Probes 17(1), 15–20 (2003).
   Google Scholar
• Cameron J, Holla L, Kulseth MA, Leren TP, Berge KE. Splice-site mutation c. 313+ 1, G> A in intron 3 of the LDL receptor gene results in transcripts with skipping of exon 3 and inclusion of intron 3. Clin. Chim. Acta 403(1–2), 131–135 (2009).
   Google Scholar
• Newton C, Graham A, Heptinstall L et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 17(7), 2503–2516 (1989).
   Google Scholar
• Taylor A, Wang D, Patel K et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin. Genet. 77(6), 572–580 (2010).
   Google Scholar
• Bodamer OA, Bercovich D, Schlabach M, Ballantyne C, Zoch D, Beaudet AL. Use of denaturing HPLC to provide efficient detection of mutations causing familial hypercholesterolemia. Clin. Chem. 48(11), 1913–1918 (2002).
   Google Scholar
• Whittall RA, Scartezini M, Li K et al. Development of a high-resolution melting method for mutation detection in familial hypercholesterolaemia patients. Ann. Clin. Biochem. 47(Pt 1), 44–55 (2010).
   Google Scholar
• Bunn CF, Lintott CJ, Scott RS, George PM. Comparison of SSCP and DHPLC for the detection of LDLR mutations in a New Zealand cohort. Hum. Mutat. 19(3), 311–311 (2002).
   Google Scholar
• Kindt I, Huijgen R, Boekel M et al. Quality assessment of the genetic test for familial hypercholesterolemia in the Netherlands. Cholesterol 2013, 531658 (2013).
   Google Scholar
• Nordestgaard BG, Chapman MJ, Humphries SE et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur. Heart J. 4, 3478–3490 (2013). • Recent Recommendations For Fh Diagnosis, Treatment And Screening.
   Google Scholar
• Nherera L, Marks D, Minhas R, Thorogood M, Humphries SE. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 97(14), 1175–1181 (2011).
   Google Scholar
• O’Brien EC, Roe MT, Fraulo ES et al. Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry. Am. Heart J. 167(3), 342–349 e317 (2014).
   Google Scholar
• Hollands GJ, Armstrong D, Macfarlane A, Crook MA, Marteau TM. Patient accounts of diagnostic testing for familial hypercholesterolaemia: comparing responses to genetic and non-genetic testing methods. BMC Med. Genet. 13, 87 (2012).
   Google Scholar
• Van Maarle MC, Stouthard ME, Marang-Van De Mheen PJ, Klazinga NS, Bonsel GJ. How disturbing is it to be approached for a genetic cascade screening programme for familial hypercholesterolaemia? Psychological impact and screenees’ views. Community Genet. 4(4), 244–252 (2001).
   Google Scholar
• Hardcastle SJ, Legge E, Laundy CS et al. Patients’ perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatment. Int. J. Behav. Med. (2014) (In Press).
   Google Scholar
• Solanas-Barca M, De Castro-Orós I, Mateo-Gallego R et al. Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia. Atherosclerosis 222(2), 449–455 (2012).
   Google Scholar
• Marduel M, Ouguerram K, Serre V et al. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p. Leu167del mutation. Hum. Mutat. 34(1), 83–87 (2013). • An APOE Mutation Is Associated With Fh.
   Google Scholar
• Awan Z, Choi HY, Stitziel N et al. APOE p. Leu167del mutation in familial hypercholesterolemia. Atherosclerosis 231(2), 218–222 (2013).
   Google Scholar
• Teslovich TM, Musunuru K, Smith AV et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707–713 (2010).
   Google Scholar
• Leren TP, Manshaus T, Skovholt U et al. Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program. Semin. Vasc. Med. 4(01), 75–85 (2004).
   Google Scholar
• Starr B, Hadfield SG, Hutten BA et al. Development of sensitive and specific age-and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin. Chem. Lab. Med. 46(6), 791–803 (2008).
   Google Scholar
• Talmud PJ, Shah S, Whittall R et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case–control study. Lancet 381, 1293–1301 (2013). •• Demonstrates The Use Of Gene Scores To Distinguish Between Monogenic And Polygenic Causes Of Fh.
   Google Scholar
• Johansen CT, Dube JB, Loyzer MN et al. LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias. J. Lipid Res. 55(4), 765–772 (2014). •• Design Of A Targeted Resequencing Gene Panel To Identify Mutations In Dyslipidemia Patients.
   Google Scholar
• Standards for clinical use of genetic variants. Nat. Genet. 46(2), 93 (2014).
   Google Scholar
• Gray VE, Kukurba KR, Kumar S. Performance of computational tools in evaluating the functional impact of laboratory-induced amino acid mutations. Bioinformatics 28(16), 2093–2096 (2012).
   Google Scholar
• Green RC, Berg JS, Grody WW et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15(7), 565–574 (2013).
   Google Scholar